keyword
MENU ▼
Read by QxMD icon Read
search

benzodiazepines and sleep

keyword
https://www.readbyqxmd.com/read/29761479/antidepressants-for-insomnia-in-adults
#1
REVIEW
Hazel Everitt, David S Baldwin, Beth Stuart, Gosia Lipinska, Andrew Mayers, Andrea L Malizia, Christopher Cf Manson, Sue Wilson
BACKGROUND: Insomnia disorder is a subjective condition of unsatisfactory sleep (e.g. sleep onset, maintenance, early waking, impairment of daytime functioning). Insomnia disorder impairs quality of life and is associated with an increased risk of physical and mental health problems including anxiety, depression, drug and alcohol abuse, and increased health service use. hypnotic medications (e.g. benzodiazepines and 'Z' drugs) are licensed for sleep promotion, but can induce tolerance and dependence, although many people remain on long-term treatment...
May 14, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29760940/analyses-of-non-benzodiazepine-induced-adverse-events-and-prognosis-in-elderly-patients-based-on-the-japanese-adverse-drug-event-report-database
#2
Yoshihiro Noguchi, Anri Ueno, Hayato Katsuno, Manami Otsubo, Aki Yoshida, Yuta Kanematsu, Ikuto Sugita, Tomoya Tachi, Teruo Tsuchiya, Hitomi Teramachi
Background: The contents of the guidelines for the use of non-benzodiazepines (Z-drugs) differ slightly between THE JAPANESE SOCIETY OF SLEEP RESEARCH and THE JAPAN GERIATRIC SOCIETY, and the recommended directions are conflicting. Therefore, we analyzed the use of the Japanese Adverse Drug Event Report database (JADER) for identifying adverse events (AEs) caused by Z-drugs and clarifying their occurrence trend and prognosis. Methods: The signal value for comparison was calculated by using the proportional reporting ratio (PRR) and chi-squared test (χ2 ) results of data of elderly and non-elderly patients...
2018: Journal of Pharmaceutical Health Care and Sciences
https://www.readbyqxmd.com/read/29760253/deprescribing-benzodiazepine-receptor-agonists-evidence-based-clinical-practice-guideline
#3
Kevin Pottie, Wade Thompson, Simon Davies, Jean Grenier, Cheryl A Sadowski, Vivian Welch, Anne Holbrook, Cynthia Boyd, Robert Swenson, Andy Ma, Barbara Farrell
OBJECTIVE: To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper and stop benzodiazepine receptor agonists (BZRAs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. METHODS: The overall team comprised 8 clinicians (1 family physician, 2 psychiatrists, 1 clinical psychologist, 1 clinical pharmacologist, 2 clinical pharmacists, and 1 geriatrician) and a methodologist; members disclosed conflicts of interest...
May 2018: Canadian Family Physician Médecin de Famille Canadien
https://www.readbyqxmd.com/read/29759270/drugs-used-in-parasomnia
#4
REVIEW
Paola Proserpio, Michele Terzaghi, Raffaele Manni, Lino Nobili
Patient education and behavioral management represent the first treatment approaches to the patient with parasomnia, especially in case of disorders of arousal (DOA). A pharmacologic treatment of DOA may be useful when episodes are frequent and persist despite resolution of predisposing factors, are associated with a high risk of injury, or cause significant impairment, such as excessive sleepiness. Approved drugs for DOA are still lacking. The most commonly used medications are benzodiazepines and antidepressants...
June 2018: Sleep Medicine Clinics
https://www.readbyqxmd.com/read/29759268/prescription-drugs-used-in-insomnia
#5
REVIEW
Sylvie Dujardin, Angelique Pijpers, Dirk Pevernagie
The scope of this article is to review the effects on sleep of prescription drugs that are commonly prescribed for chronic insomnia in adults. The following groups are discussed: benzodiazepines and its receptor agonists, the dual orexin receptor antagonist suvorexant, melatonin and its receptor agonists, sedating antidepressants, and antipsychotics. Together with the neurobiologic and pharmacologic properties of these drugs, clinical effects are described, including subjective and objective effects on sleep duration, continuity, and architecture...
June 2018: Sleep Medicine Clinics
https://www.readbyqxmd.com/read/29753639/nrem-parasomnias-a-treatment-approach-based-upon-a-retrospective-case-series-of-512-patients
#6
Panagis Drakatos, Lucy Marples, Rexford Muza, Sean Higgins, Nadia Gildeh, Raluca Macavei, Eptehal M Dongol, Alexander Nesbitt, Ivana Rosenzweig, Elaine Lyons, Grainne d'Ancona, Joerg Steier, Adrian J Williams, Brian D Kent, Guy Leschziner
BACKGROUND: Non-REM parasomnias are not uncommon conditions in the general population. Current treatment options are based on small case series and reports. In this study, we aimed to present the clinical experience from a large cohort of patients. PATIENTS: Five hundred and twelve patients with Non-REM parasomnia or parasomnia overlap disorder (POD), who had undergone a video polysomnography and were exposed to treatment, were retrospectively identified. Treatment outcome was assessed based on patients' reports, and treatment approach on a locally accepted hierarchy of interventions...
April 10, 2018: Sleep Medicine
https://www.readbyqxmd.com/read/29749262/comparison-of-the-effects-of-melatonin-and-oxazepam-on-anxiety-levels-and-sleep-quality-in-patients-with-st-segment-elevation-myocardial-infarction-following-primary-percutaneous-coronary-intervention-a-randomized-clinical-trial
#7
Padideh Ghaeli, Mohammad Solduzian, Shaghayegh Vejdani, Azita Hajhossein Talasaz
BACKGROUND: Anxiety and sleep disorders are prevalent problems in patients presenting with ST-segment-elevation myocardial infarction (STEMI). Usually, these problems are managed by benzodiazepines, which-albeit effective-could cause adverse effects and drug interaction. OBJECTIVE: This study was designed to compare the effects of melatonin and oxazepam in the management of anxiety and insomnia on patients following primary percutaneous coronary intervention (PCI) with a view to providing a safer alternative...
May 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29735241/use-of-a-gabapentin-protocol-for-the-management-of-alcohol-withdrawal-a-preliminary-experience-expanding-from-the-consultation-liaison-psychiatry-service
#8
Jonathan G Leung, Daniela B Rakocevic, Nicholas D Allen, Elliot M Handler, Bruno A Perossa, Kristin L Borreggine, Amy L Stark, Hannah K Betcher, Daniel K Hosker, Blaine A Minton, Benjamin R Braus, Ross A Dierkhising, Kemuel L Philbrick
BACKGROUND: Benzodiazepines are the conventional mainstay to manage alcohol withdrawal; however, patients are subsequently at increased risk for poor sleep, cravings, and return to drinking. Research on alternative pharmacologic agents to facilitate safe alcohol withdrawal is scant. Gabapentin is one medication shown in small studies to reduce the need for benzodiazepines in the setting of alcohol withdrawal. The continuation of gabapentin after alcohol withdrawal appears to be safe during early sobriety and may aid in reducing alcohol-related cravings or returning to alcohol consumption...
March 21, 2018: Psychosomatics
https://www.readbyqxmd.com/read/29720564/evidence-that-sedative-effects-of-benzodiazepines-involve-unexpected-gaba-a-receptor-subtypes-quantitative-observation-studies-in-rhesus-monkeys
#9
Angela N Duke, Zhiqiang Meng, Donna M Platt, John R Atack, Gerard R Dawson, David S Reynolds, V V N Phani Babu Tiruveedhula, Guanguan Li, Michael Rajesh Stephen, Werner Sieghart, James M Cook, James K Rowlett
Using non-human primates, we introduced a new set of behavioral categories for observable sedative effects based on pediatric anesthesiology classifications. We examined the effects of alprazolam and diazepam (non-selective benzodiazepines), zolpidem (preferential binding to α1 subunit-containing GABAA receptors), HZ-166 (8-ethynyl-6-(2'-pyridine)-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic acid ethyl ester; functionally selective for α2 and α3 subunit-containing GABAA receptors), MRK-696 (7-cyclobutyl-6-(2-methyl-2H-1,2,4-triazol-2-ylmethoxy)-3-(2-flurophenyl)-1,2,4-triazolo(4,3-b)pyridazine; no selectivity but partial intrinsic activity), and TPA023B (6,2'-difluro-5'-(3-(1-hydroxy-1-methylethyl)imidazo(1,2-b((1,2,4)triazin-7-yl)(1,1'-biphenyl)-2-carbonitrile; selectivity for α2, α3, α5 subunit-containing GABAA receptors) using quantitative behavioral observation techniques in rhesus monkeys...
May 2, 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29706359/considerations-in-treating-insomnia-during-pregnancy-a-literature-review
#10
REVIEW
Simriti K Chaudhry, Leah C Susser
BACKGROUND: The prevalence of pregnancy-associated insomnia is high. Although insomnia may flow from normal physiologic features of pregnancy, it may also be an early warning sign of a relapse, or a trigger for a relapse, of a psychiatric illness. Those at risk for psychiatric illnesses may require medications as well as behavioral and psychotherapeutic interventions, to prevent relapse in the perinatal period. Unfortunately, few reviews of psychotropics used to treat pregnancy-related sleep disorders exist...
March 21, 2018: Psychosomatics
https://www.readbyqxmd.com/read/29705831/deprescribing-benzodiazepines-in-older-patients-impact-of-interventions-targeting-physicians-pharmacists-and-patients
#11
REVIEW
Brendan J Ng, David G Le Couteur, Sarah N Hilmer
Benzodiazepines (BZDs; including the related Z-drugs) are frequently targets for deprescribing; long-term use in older people is harmful and often not beneficial. BZDs can result in significant harms, including falls, fractures, cognitive impairment, car crashes and a significant financial and legal burden to society. Deprescribing BZDs is problematic due to a complex interaction of drug, patient, physician and systematic barriers, including concern about a potentially distressing but rarely fatal withdrawal syndrome...
April 28, 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29695101/triphlorethol-a-a-dietary-polyphenol-from-seaweed-decreases-sleep-latency-and-increases-non-rapid-eye-movement-sleep-in-mice
#12
Minseok Yoon, Suengmok Cho
In our previous studies, we have demonstrated that marine polyphenol phlorotannins promote sleep through the benzodiazepine site of the gamma-aminobutyric acid type A (GABAA ) receptors. In this follow-up study, the sleep-promoting effects of triphlorethol A, one of the major phlorotannin constituents, were investigated. The effect of triphlorethol A on sleep-wake architecture and profiles was evaluated based on electroencephalogram and electromyogram data from C57BL/6N mice and compared with the well-known hypnotic drug zolpidem...
April 24, 2018: Marine Drugs
https://www.readbyqxmd.com/read/29674967/no-acute-effects-of-cannabidiol-on-the-sleep-wake-cycle-of-healthy-subjects-a-randomized-double-blind-placebo-controlled-crossover-study
#13
Ila M P Linares, Francisco S Guimaraes, Alan Eckeli, Ana C S Crippa, Antonio W Zuardi, Jose D S Souza, Jaime E Hallak, José A S Crippa
Cannabidiol (CBD) is a component of Cannabis sativa that has a broad spectrum of potential therapeutic effects in neuropsychiatric and other disorders. However, few studies have investigated the possible interference of CBD on the sleep-wake cycle. The aim of the present study was to evaluate the effect of a clinically anxiolytic dose of CBD on the sleep-wake cycle of healthy subjects in a crossover, double-blind design. Twenty-seven healthy volunteers that fulfilled the eligibility criteria were selected and allocated to receive either CBD (300 mg) or placebo in the first night in a double-blind randomized design (one volunteer withdrew from the study)...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29671244/assessment-of-the-availability-cost-and-motivations-for-use-over-time-of-the-new-psychoactive-substances-benzodiazepines-diclazepam-flubromazepam-and-pyrazolam-in-the-uk
#14
Rachelle Abouchedid, Thea Gilks, Paul I Dargan, John R H Archer, David M Wood
INTRODUCTION: There has been increasing interest in the availability of non-prescription benzodiazepines and their sale as new psychoactive substances. We wanted to determine UK availability from Internet suppliers and motivations for use of three benzodiazepines (diclazepam, flubromazepam, and pyrazolam). METHODS: In November 2014 and March 2016, using the European Monitoring Centre for Drugs and Drug Addiction Snapshot Methodology, Internet search engines ( google...
April 18, 2018: Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology
https://www.readbyqxmd.com/read/29663484/association-between-psychotropic-medications-and-presence-of-sleep-bruxism-a-systematic-review
#15
REVIEW
Gilberto Melo, Kamile Leonardi Dutra, Rubens Rodrigues Filho, Adriana de Oliveira Lira Ortega, André Luís Porporatti, Bruce Dick, Carlos Flores-Mir, Graziela De Luca Canto
The purpose of this study was to systematically review the literature for studies that investigated the association between use of psychotropic medications and presence of sleep bruxism (SB). Observational studies were selected in a two-phase process. Searches were performed on six electronic databases and a grey literature search was conducted on three databases. SB diagnosis was based on questionnaires or clinical examinations; no polysomnography exams were performed. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional Studies...
April 16, 2018: Journal of Oral Rehabilitation
https://www.readbyqxmd.com/read/29649764/sleep-after-intranasal-progesterone-vs-zolpidem-and-placebo-in-postmenopausal-women-a-randomized-double-blind-cross-over-study
#16
P Schüssler, M Kluge, M Adamczyk, M E Beitinger, P Beitinger, A Bleifuss, S Cordeiro, C Mattern, M Uhr, T C Wetter, A Yassouridis, R Rupprecht, E Friess, A Steiger
CONTEXT: The loss of progesterone during menopause is linked to sleep complaints of the affected women. Previously we demonstrated sleep promoting effects of oral progesterone replacement in postmenopausal women. The oral administration of progesterone, however, is compromised by individual differences in bioavailability and metabolism of the steroid. OBJECTIVE: We compared the sleep-endocrine effects after intranasal progesterone (MPP22), zolpidem and placebo in healthy postmenopausal women...
April 4, 2018: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/29594870/treatment-strategies-for-dravet-syndrome
#17
REVIEW
Kelly G Knupp, Elaine C Wirrell
Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomic dysfunction). Complete seizure control is generally not achievable with current therapies, and the goals of treatment are to balance reduction of seizure burden with adverse effects of therapies...
March 28, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29568975/safety-of-brotizolam-in-hospitalized-patients
#18
Ophir Lavon, Shmuel Bejel
PURPOSE: The objective of this study was to evaluate the safety of brotizolam in hospitalized patients. METHODS: A single-center, comparative retrospective cohort analysis of patients hospitalized in internal medicine wards. Patients treated with brotizolam were compared to patients not treated with any benzodiazepines during hospitalization. Primary outcome was any of the following safety events: mechanical ventilation, delirium, and falls. RESULTS: Six hundred patients were included after exclusion in the final analysis; 300 treated with brotizolam (treatment) and 300 not treated with any benzodiazepines (comparator)...
March 22, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29513209/pharmacotherapy-in-temporomandibular-disorders-a-review
#19
Aviv Ouanounou, Michael Goldberg, Daniel A Haas
Temporomandibular disorder (TMD) is a collective term that includes disorders of the temporomandibular joint (TMJ) and of the masticatory muscles and their associated structures. TMDs are characterized by pain, joint sounds and restricted mandibular movement, and drugs are widely used in the management of that pain. Pharmacological agents commonly used for the treatment of TMDs include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, muscle relaxants, antidepressants, anticonvulsants and benzodiazepines...
July 2017: Journal—Canadian Dental Association, Journal de L'Association Dentaire Canadienne
https://www.readbyqxmd.com/read/29498534/low-dose-nocturnal-dexmedetomidine-prevents-icu-delirium-a-randomized-placebo-controlled-trial
#20
Yoanna Skrobik, Matthew S Duprey, Nicholas S Hill, John W Devlin
RATIONALE: Dexmedetomidine is associated with less delirium than benzodiazepines and better sleep architecture than either benzodiazepines or propofol; its effect on delirium and sleep when administered at night to patients requiring sedation remains unclear. OBJECTIVES: To determine if nocturnal dexmedetomidine prevents delirium and improves sleep in critically ill adults. METHODS: This two-center, double-blind, placebo-controlled trial randomized 100 delirium-free critically ill adults receiving sedatives to receive nocturnal (9:30 p...
May 1, 2018: American Journal of Respiratory and Critical Care Medicine
keyword
keyword
74589
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"